October 2012 | Oncology Live®

November 13, 2012

A deeper understanding of androgen receptor signaling in castration-resistant prostate cancer has created an opportunity to deliver more effective therapies earlier in the treatment timeline.

November 12, 2012

Novel combinations of hormonal therapies with targeted agents show promise for improved outcomes and are likely to become part of a new paradigm for managing patients.

November 12, 2012

An interview with Nicholas J. Vogelzang, MD, a researcher who has changed the course of cancer treatment by helping to develop therapies for prostate cancer, kidney cancer, bladder cancer, testicular cancer, and mesothelioma.

November 05, 2012

Suzanne L. Topalian, MD, has led clinical development of monoclonal antibodies to treat patients with melanoma and other solid tumors, including those targeting the PD-1 T cell co-receptor.

November 02, 2012

As an increasing number of cancers are considered chronic diseases treatable with continuous drug delivery, it is essential that our vocabulary describing the side effects experienced by our patients more appropriately reflects this new paradigm.

November 01, 2012

The development of targeted agents aimed at aurora kinases has proceeded slowly, and the future may lie in combination therapies.

October 31, 2012

Increasing evidence suggests that the ability to outsmart the body's immune response represents a hallmark of tumor development.

October 30, 2012

Despite the fact that pazopanib and cabozantinib are not yet approved, researchers are already trying to determine the best way to integrate them into existing treatment regimens.

October 29, 2012

In early clinical trials, small-molecule inhibitors have demonstrated improvement in response rates in elderly patients with chronic lymphocytic leukemia.

October 26, 2012

An overview of studies looking at the potential of osteoclast inhibitors in the prevention of breast cancer recurrences in the adjuvant setting.

October 24, 2012

As more individual cancers undergo molecular profiling, we can anticipate that the scenario in which a targeted drug demonstrates rather remarkable clinical activity against a rare tumor type will become increasingly common.

October 24, 2012

Patients who received sipuleucel-T developed immune parameters that correlated with improved overall survival suggesting that these parameters should be the focus of further studies on the treatment.